Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate initiated with data expected in H1 2021Phase 1/2 St
… title: Phase 1b/2 trial results of intravitreal sepofarsen RNA therapy in Leber congenital amaurosis 10 … investigator of the ProQR Phase 1/2 clinical trial of sepofarsen Professor and Director of Vitreoretinal Diseases …
Encouraging clinical data reported from Phase 1/2 trial of sepofarsen for LCA10
Initial clinical data from Phase 1/2 trial of QR-421a for Usher syndrome type 2 on track for Q1 2020
QR-1123 Investigational New Drug application active for autosomal dominant re
… far with the initiation of both the Phase 2/3 trial for sepofarsen and the proof of concept trial for QR-421a in … to patients.” Corporate Highlights and Business Update Sepofarsen (formerly QR-110) for LCA10 In April 2019, the …
… Results Post-hoc analyses from Illuminate trial of sepofarsen demonstrate an encouraging efficacy signal when … outcome of the primary analysis in the Illuminate trial of sepofarsen, we believe that the post-hoc analyses and the …
… The key deliverables for “ProQR Vision 2023” include: Sepofarsen (formerly QR-110) for Leber's congenital amaurosis … Officer at ProQR. “Clinical data for our lead program, sepofarsen, has presented strong potential for this medicine …
… investigator of the ProQR Phase 1/2 clinical trial of sepofarsen and Chairman and Head of the Department of … PhD, co-investigator of the PQ-110-001 clinical trial of sepofarsen and Research Professor of Ophthalmology at the …
Senior leader with extensive global rare disease commercialization experience
Top-line data from Phase 2/3 pivotal Illuminate trial of sepofarsen for CEP290-mediated LCA10 on track for H1 2022
… Western world have LCA10 because of this mutation. About SepofarsenSepofarsen (QR-110) is being evaluated in the pivotal Phase … splicing of the mRNA and non-functional CEP290 protein. Sepofarsen is designed to enable normal splicing, resulting …
… targets in H2 2022 Company plans to discuss findings from sepofarsen Illuminate trial with regulators and provide an … have LCA10 because of this mutation. About s epofarsen Sepofarsen (QR-110) is an investigational RNA therapy …